Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,612.00
(
-0.46%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
105.03
(
0.57%
)
Bitcoin
70,700.00
(
1.15%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JohnWayne post# 207853

Tuesday, 01/10/2017 5:05:52 PM

Tuesday, January 10, 2017 5:05:52 PM

Post# of 257262

Will be interesting to see if/how the rest of the class will be able to make up for the timing disadvantage in terms of differentiation, either based on data or marketing activities.

In due course, the differentiation will be based on data, IMO. So many regimens are being tested in first-line NSCLC that some of them are bound to perform well enough (relative to Keytruda + chemo) to take significant market share.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now